The clearance of therapeutic monoclonal antibodies (mAbs) typically does not involve CYP450-mediated metabolism or interaction with cell membrane transporters, therefore the pharmacokinetic interaction of mAbs and small molecule drugs is limited. However, a drug may affect the clearance of mAbs through the modulation of immune response (e.g., methotrexate reduces the clearance of infliximab, adalimumab, and golimumab, possibly due to methotrexate's inhibitory effect on the formation of antibodies against the mAbs). In addition, mAbs that are cytokine modulators may modify the metabolism of drugs through their effects on the regulation pathways of P450 enzymes. For example, cytokine modulators such as tocilizumab (anti-IL-6 receptor antibody) may reverse the "inhibitory" effect of IL-6 on CYP substrates, resulting in a "normalization" of CYP activities. Finally, a drug may alter the clearance of mAbs by either increasing or reducing the levels of expression of targets of mAbs on the cell surface. For instance, statins and fibrates induce PCSK9 expression and therefore increase cellular uptake and clearance of alirocumab and evolocumab, anti-PCSK9 antibodies. In the present review, we will provide an overview on the pharmacokinetics properties of mAbs as related to the most relevant examples of mAbs-small molecule drug interaction.
Pharmacokinetic interactions of monoclonal antibodies / N. Ferri, S. Bellosta, L. Baldessin, D. Boccia, G. Racagni, A. Corsini. - In: PHARMACOLOGICAL RESEARCH. - ISSN 1043-6618. - 111(2016 Sep), pp. 592-599.
Pharmacokinetic interactions of monoclonal antibodies
N. FerriPrimo
;S. BellostaSecondo
;G. RacagniPenultimo
;A. CorsiniUltimo
2016
Abstract
The clearance of therapeutic monoclonal antibodies (mAbs) typically does not involve CYP450-mediated metabolism or interaction with cell membrane transporters, therefore the pharmacokinetic interaction of mAbs and small molecule drugs is limited. However, a drug may affect the clearance of mAbs through the modulation of immune response (e.g., methotrexate reduces the clearance of infliximab, adalimumab, and golimumab, possibly due to methotrexate's inhibitory effect on the formation of antibodies against the mAbs). In addition, mAbs that are cytokine modulators may modify the metabolism of drugs through their effects on the regulation pathways of P450 enzymes. For example, cytokine modulators such as tocilizumab (anti-IL-6 receptor antibody) may reverse the "inhibitory" effect of IL-6 on CYP substrates, resulting in a "normalization" of CYP activities. Finally, a drug may alter the clearance of mAbs by either increasing or reducing the levels of expression of targets of mAbs on the cell surface. For instance, statins and fibrates induce PCSK9 expression and therefore increase cellular uptake and clearance of alirocumab and evolocumab, anti-PCSK9 antibodies. In the present review, we will provide an overview on the pharmacokinetics properties of mAbs as related to the most relevant examples of mAbs-small molecule drug interaction.File | Dimensione | Formato | |
---|---|---|---|
2016 Pharm Res Pharmacokinetics Interactions of Monoclonal Antibodies.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.15 MB
Formato
Adobe PDF
|
1.15 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.